December 14, 2006
Qualyst, a company created based on discoveries made at the UNC School of Pharmacy, announced that Covance Laboratories Inc., has licensed the use of Qualyst’s B-CLEAR® system to provide its pharmaceutical and biotechnology sponsors with pharmacokinetic services.
B-CLEAR® is a sandwich-cultured hepatocyte system for the in vitro assessment and in vivo prediction of critical pharmacokinetic properties, including hepatobiliary disposition, hepatic uptake, hepatic accumulation, biliary clearance and drug transport. B-CLEAR® offers research organizations the ability to generate physiologically-relevant data and enable decision making in critical areas related to hepatic transport and adverse drug interactions, helping to avoid costly drug-development challenges and enabling better prediction of bioavailability, pharmacokinetics, species-specific drug dosing, and candidate selection.
Covance Laboratories, Inc., is one of the world’s largest and most comprehensive drug development services companies.
Qualyst was founded in 2001 on breakthrough research by Kim Brouwer, PharmD; Gary Pollack, PhD; and Dhiren Thakker, PhD; three professors at the UNC School of Pharmacy. For many years, Qualyst’s founders have pursued basic research to understand the fundamental principles behind processes of absorption, distribution, metabolism and excretion at cellular and molecular levels, and to relate these processes to drug toxicity.
Latest News
Dean Angela Kashuba receives Carolina Alumni Faculty Service Award
RASP poster presentations capture student research
